Athersys could raise an additional $12.8M from unnamed institutional investor


For months, Athersys has been restructuring its operations and trying to raise the cash it needs to complete the testing and commercialization of its adult stem cell therapy.

Previous Integrated health care benefits: A modern strategy for improved health and cost savings
Next Patti Payne's Cool Pads: Dwell Development owners sell their Columbia City home

No Comment

Leave a reply

Your email address will not be published.